A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform

In 2012, the first cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) were identified. Since then, more than 1,000 cases of MERS-CoV infection have been confirmed; infection is typically associated with considerable morbidity and, in approximately 30% of cases, morta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virol
Autors principals: Malczyk, Anna H., Kupke, Alexandra, Prüfer, Steffen, Scheuplein, Vivian A., Hutzler, Stefan, Kreuz, Dorothea, Beissert, Tim, Bauer, Stefanie, Hubich-Rau, Stefanie, Tondera, Christiane, Eldin, Hosam Shams, Schmidt, Jörg, Vergara-Alert, Júlia, Süzer, Yasemin, Seifried, Janna, Hanschmann, Kay-Martin, Kalinke, Ulrich, Herold, Susanne, Sahin, Ugur, Cichutek, Klaus, Waibler, Zoe, Eickmann, Markus, Becker, Stephan, Mühlebach, Michael D.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4645655/
https://ncbi.nlm.nih.gov/pubmed/26355094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01815-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars